SCHEMBL5338369

SCHEMBL5338369

Cc1ccc(CN2CCCC2)c(N2CCN(C(=O)OC(C)(C)C)CC2)c1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 10/20 0.49
ABHD6 Q9BV23 9/20 0.49
PLA2G7 Q13093 7/20 0.49
CYP2D6 P10635 1/20 0.49
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
CYP2C19 P33261 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GPR119 Q8TDV5 2/20 0.46
LMNA P02545 2/20 0.45
MAPT P10636 2/20 0.45
GRIN2B Q13224 2/20 0.44
VEGFA P15692 1/20 0.44
EGLN1 Q9GZT9 1/20 0.44
TSHR P16473 1/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16744505 0.95 MGLL (0.54) MGLLABHD6PLA2G7CYP2D6MEN1
SCHEMBL16577083 0.88 MGLL (0.56) MGLLABHD6PLA2G7CYP2D6SMN1; SMN2
SCHEMBL15265005 0.86 MGLL (0.50) MGLLABHD6PLA2G7CYP2D6MEN1
SCHEMBL5331677 0.85 MGLL (0.68) MGLLABHD6PLA2G7CYP2D6MAPT
SCHEMBL5340446 0.85 MGLL (0.49) MGLLABHD6PLA2G7CYP2D6MEN1
SCHEMBL25487320 0.85 GPR119 (0.48) MGLLABHD6PLA2G7CYP2D6GPR119
SCHEMBL5335100 0.84 PLA2G7 (0.61) MGLLABHD6PLA2G7MEN1KMT2A
SCHEMBL5335298 0.83 MGLL (0.60) MGLLABHD6PLA2G7MEN1KMT2A
SCHEMBL15094187 0.83 MGLL (0.70) MGLLABHD6PLA2G7CYP2D6VEGFA
SCHEMBL15094180 0.83 MGLL (0.70) MGLLABHD6PLA2G7CYP2D6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
EP-1368340-B1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS LILLY CO ELI (US) 2005-08-10 EP disclosed
US-20040092507-A1 Melanocortin receptor agonists ELI LILLY AND COMPANY 2004-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092507-A1 Melanocortin receptor agonists MC1R, MC4R, MC5R MGLL 986/4885ABHD6 1367/4885PLA2G7 1585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.